| Literature DB >> 32991394 |
Nicole K Zagelbaum Ward1, Carlos Linares-Koloffon2, Alba Posligua3, Liliya Gandrabur3, Woo Young Kim3, Kirk Sperber3, Amy Wasserman3, Julia Ash3.
Abstract
Systemic lupus erythematosus (SLE) is a complex connective tissue disease that can potentially affect every organ of the human body. In some cases, SLE may present with diverse cardiac manifestations including pericarditis, myocarditis, valvular disease, atherosclerosis, thrombosis, and arrhythmias. Heart disease in SLE is associated with increased morbidity and mortality. It is unclear whether traditional treatments for coronary artery disease significantly impact mortality in this population. Current therapeutic agents for SLE include glucocorticoids, hydroxychloroquine, mycophenolate mofetil, azathioprine, methotrexate, cyclophosphamide, and B cell-directed therapies. This article will provide a comprehensive review and update on this important disease state.Entities:
Mesh:
Year: 2022 PMID: 32991394 DOI: 10.1097/CRD.0000000000000358
Source DB: PubMed Journal: Cardiol Rev ISSN: 1061-5377 Impact factor: 2.644